ALP Bio AG
Precise prediction of immunogenicity risks in biologics.
Most biologics fail not because they lack potency, but because the immune system disagrees. Undetected immunogenic responses in the form of anti-drug antibodies (ADAs) can derail clinical trials and cost pharma billions. Today, ADA risk often becomes visible only during late-stage trials. ALP AI fixes this. We combine tonsil-derived immune organoids and generative AI to predict and prevent ADA risk in early R&D, saving years and reducing failure rates.
Founded by scientists and engineers from Caltech, ETH Zurich, Stanford, and MIT, ALP AI offers the first scalable platform for human immune response validation. With a $300B+ biologics market growing rapidly, we are building the standard for immunogenicity intelligence.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
30.04.2026
ALP Bio AG raises CHF 1.75 million pre-seed to de-risk antibody development (startupticker.ch)
30.04.2026
ALP Bio raises USD 2.2M pre-seed to address immunogenicity risk in antibody development (venturekick.ch)
No milestones
No Jobs
No videos and documents
Venture Kick
Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.
ALP Bio AG
Precise prediction of immunogenicity risks in biologics.
Website:
alpbio.ai
Headquarter:
Schlieren
Foundation Date:
January 2026
Technology:
- Biotech
Sectors:
- Antibodies
- Biotech
- Drug development platforms
- Machine Learning / AI
Support received
